Literature DB >> 19200010

Therapy in prion diseases: from molecular and cellular biology to therapeutic targets.

Carmen Krammer1, Ina Vorberg, Hermann M Schätzl, Sabine Gilch.   

Abstract

Prion diseases are infectious and fatal neurodegenerative disorders of man and animals which are characterized by spongiform degeneration in the central nervous system. In human diseases, the manifestation can be sporadic, familial or acquired by infection. Prion disorders are caused by the accumulation of an aberrantly folded isoform of the cellular prion protein (PrP(c)), commonly named PrP(Sc). Although prion diseases are usually rare, they have the potential to be transferred within and also between species by infection processes, giving then raise even to epidemic scenarios. As pathology is obviously restricted to the central nervous system pre-mortem diagnosis is usually hard to achieve. Promising approaches towards the development of therapeutic and even prophylactic anti-prion regimens were recently made. However, only a profound knowledge of the infectious agent and its replication strategy enables the design of effective anti-prion strategies. Cell culture models were highly instrumental in uncovering fundamental aspects of prion propagation. In this chapter, the cellular and molecular biology of prion proteins in general is discussed and prophylactic and therapeutic concepts derived thereof are introduced. In particular, emphasis is put on strategies targeting PrP(c) which is absolutely needed as substrate for prion conversion, and on intrinsic cellular clearance mechanisms for prions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200010     DOI: 10.2174/1871526510909010003

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  7 in total

1.  Neuronal low-density lipoprotein receptor-related protein 1 binds and endocytoses prion fibrils via receptor cluster 4.

Authors:  Angela Jen; Celia J Parkyn; Roy C Mootoosamy; Melanie J Ford; Alice Warley; Qiang Liu; Guojun Bu; Ilia V Baskakov; Søren Moestrup; Lindsay McGuinness; Nigel Emptage; Roger J Morris
Journal:  J Cell Sci       Date:  2010-01-15       Impact factor: 5.285

Review 2.  Therapies for human prion diseases.

Authors:  Peter K Panegyres; Elizabeth Armari
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 3.  Prion-like propagation of cytosolic protein aggregates: insights from cell culture models.

Authors:  Carmen Krammer; Hermann M Schätzl; Ina Vorberg
Journal:  Prion       Date:  2009-10-04       Impact factor: 3.931

4.  Impairment of autophagy in scrapie-infected transgenic mice at the clinical stage.

Authors:  Óscar López-Pérez; Janne Markus Toivonen; Alicia Otero; Laura Solanas; Pilar Zaragoza; Juan José Badiola; Rosario Osta; Rosa Bolea; Inmaculada Martín-Burriel
Journal:  Lab Invest       Date:  2019-09-02       Impact factor: 5.662

5.  Interaction of Peptide Aptamers with Prion Protein Central Domain Promotes α-Cleavage of PrPC.

Authors:  Erica Corda; Xiaotang Du; Su Yeon Shim; Antonia N Klein; Jessica Siltberg-Liberles; Sabine Gilch
Journal:  Mol Neurobiol       Date:  2018-02-19       Impact factor: 5.590

6.  Combining autophagy stimulators and cellulose ethers for therapy against prion disease.

Authors:  Basant A Abdulrahman; Waqas Tahir; Katsumi Doh-Ura; Sabine Gilch; Hermann M Schatzl
Journal:  Prion       Date:  2019-01       Impact factor: 3.931

7.  The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions.

Authors:  Basant A Abdulrahman; Dalia Abdelaziz; Simrika Thapa; Li Lu; Shubha Jain; Sabine Gilch; Stefan Proniuk; Alexander Zukiwski; Hermann M Schatzl
Journal:  Sci Rep       Date:  2017-12-14       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.